Glaucoma

Timolol microdrops administered with the Nanodropper Adaptor were as effective as conventional drops at lowering IOP among patients with open-angle glaucoma and ocular hypertension, according to a study published in Ophthalmology.

Circumpapillary retinal nerve fiber layer and ganglion cell inner plexiform layer measurements may help predict visual field worsening in glaucoma, although each is more effective in different stages of disease, according to research.

Researchers are recruiting participants for a study to evaluate the efficacy of acupuncture as an adjuvant treatment for glaucoma, with preliminary results expected in 2025, according to a protocol published in JMIR Research Protocols.

An escalating monotherapy regimen was just as effective as multitherapy for most patients with untreated glaucoma, although those with higher baseline IOP may benefit from more intensive treatment, according to a study conducted in Sweden.

SpyGlass Pharma has completed enrollment in its phase 1/2 clinical trial evaluating a long-term drug delivery platform of bimatoprost for glaucoma and ocular hypertension, according to a press release.

NEW YORK — In this Healio Video Perspective from OSN New York, Nandini Venkateswaran, MD, of Massachusetts Eye and Ear Infirmary, discusses real-world data investigating the use of Dextenza in patients with glaucoma.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Long of Alcon introduces some of the company’s technologies, including the Voyager direct selective laser trabeculoplasty device.

An estimated 4.22 million U.S. adults had glaucoma in 2022, and 1.49 million had vision-affecting glaucoma, with “substantial variation” in prevalence by region and demographics, according to a study published in JAMA Ophthalmology.

Use of glucagon-like peptide-1 receptor agonists was associated with a 19% reduction in risk for glaucoma in patients with type 2 diabetes, with longer use extending the protective association, according to a study in Ophthalmology.

Concurrent use of a beta-blocker with Simbrinza delayed the onset of ocular allergy and may extend treatment duration and adherence among patients with glaucoma, according to a retrospective study in BMC Ophthalmology.